Gilead made waves on Friday with its emergency FDA approval for remdesivir quickly on the heels of a controlled trial data release. But while it’s an important first step, other COVID-19 medicines will likely be coming down the line, analysts wrote. More: Remdesivir,
read moreWhile Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at up to $4,460 per patient. That means it could easily rake in blockbuster sales this year, at least
read moreRoche scored a major win with the FDA’s backing for its COVID-19 antibody tests last week in a field marked by products of questionable quality. Now, to cover its booming production goals, Roche plans to infuse nearly half-a-billion dollars into
read moreWith less than six months to go until the U.S. elections, the drugmakers find themselves in a different position than expected at the start of the year. Because of the COVID-19 pandemic, the public will recognize pharma’s ability to innovate and help,
read moreThe Index is a first-of-its-kind opportunity for pharma companies to showcase, benchmark and measure the quality of their partnership working with patient communities More: Inaugural Patient Partnership Index 2020 launches Source: News
read moreThe first concerns the care of immunocompromised children and young people and the second antibiotics for pneumonia in hospitalised adults More: NICE publishes latest set of COVID-19 guidelines Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals